An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 111, Issue 1-2, 2008, Pages 138-146

  Southwell, Jason ^a   Chowdhury, Shafinaz F ^a,b   Gottlieb, Bruce ^a,c,d   Beitel, Lenore K ^a,c   Lumbroso, Rose ^a   Purisima, Enrico O ^b   Trifiro, Mark ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d JOHN ABBOTT COLLEGE   (Canada)

Author keywords

Androgen receptor mutation; Coactivator proteins; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; PEPTIDE DERIVATIVE; PROTEIN FXXLF; PROTEIN LXXLL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; MALE; MOLECULAR MODEL; NONHUMAN; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; WILD TYPE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; GENES, REPORTER; HAPLORHINI; KIDNEY; LUCIFERASES; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ANDROGEN; REPETITIVE SEQUENCES, NUCLEIC ACID; TRANSFECTION; TWO-HYBRID SYSTEM TECHNIQUES; VARIATION (GENETICS);

EID: 47849088181     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.04.009     Document Type: Article

References (37)

1. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 25 (2004) 276-308
2. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351 (2004) 1488-1490
3. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell. Biochem. 253 (2003) 89-101
4. He B., and Wilson E.M. The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol. Genet. Metab. 75 (2002) 293-298
5. Heinlein C.A., and Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23 (2002) 175-200
6. Gottlieb B., Beitel L.K., Wu J., Elhaji Y.A., and Trifiro M. Nuclear receptors and disease: androgen receptor. Essays Biochem. 40 (2004) 121-136
7. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22 (1994) 3181-3186
8. Choong C.S., Kemppainen J.A., Zhou Z.X., and Wilson E.M. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol. Endocrinol. 10 (1996) 1527-1535
9. Buchanan G., Yang M., Cheong A., Harris J.M., Irvine R.A., Lambert P.F., Moore N.L., Raynor M.M., Neufing P.J., Coetzee G.A., and Tilley W.D. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum. Mol. Genet. 13 (2004) 1677-1692
10. Tut T.G., Ghadessy F.J., Trifiro M.A., Pinsky L., and Yong E.L. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J. Clin. Endocrinol. Metab. 8 (1997) 3777-3782
11. Callewaert L., Christiaens V., Haelens A., Verrijdt G., Verhoeven G., and Claessens F. Implications of a polyglutamine tract in the function of the human androgen receptor. Biochem. Biophys. Res. Commun. 306 (2003) 46-52
12. Irvine R.A., Ma H., Yu M.C., Ross R.K., Stallcup M.R., and Coetzee G.A. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum. Mol. Genet. 9 (2000) 267-274
13. Ferro P., Catalano M.G., Dell'Eva R., Fortunati N., and Pfeffer U. The androgen receptor CAG repeat: a modifier of carcinogenesis?. Mol. Cell. Endocrinol. 193 (2002) 109-120
14. Alvarado C., Beitel L.K., Sircar K., Aprikian A., Trifiro M., and Gottlieb B. Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res. 65 (2005) 8514-8518
15. Steketee K., Timmerman L., Ziel-van der Made A.C., Doesburg P., Brinkmann A.O., and Trapman J. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int. J. Cancer 100 (2002) 309-317
16. Bohl C.E., Wu Z., Miller D.D., Bell C.E., and Dalton J.T. Crystal structure of the T877A human androgen receptor ligand-binding domain compared to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J. Biol. Chem. 282 (2007) 13648-13651
17. He B., Gamoe R.T., Kole A.J., Hnat A.T., Stanley T.B., An G., Stewart E.L., Kalman R.I., Minges J.T., and Wilson E.M. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear activation function dominance. Mol. Cell 16 (2004) 425-438
18. Ozers M.S., Marks B.D., Gowda K., Kupcho K.R., Ervin K.M., De Rosier T., Qadir N., Eliason H.C., Riddle S.M., and Shekhani M.S. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 46 (2007) 683-695
19. Morin P.J. β-catenin signaling and cancer. BioEssays 21 (1999) 1021-1030
20. Song L.N., Herrell R., Byers S., Shah S., Wilson E.M., and Gelmann E.P. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol. Cell. Biol. 23 (2003) 1674-1687
21. Beitel L.K., Kazemi-Esfarjani P., Kaufman M., Lumbroso R., DiGeorge A.M., Killinger D.W., Trifiro M.A., and Pinsky L. Substitution of arginine-839 by cysteine or histidine in the androgen receptor causes different receptor phenotypes in cultured cells and coordinate degrees of clinical androgen resistance. J. Clin. Invest. 94 (1994) 546-554
22. Kazemi-Esfarjani P., Trifiro M.A., and Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum. Mol. Genet. 4 (1995) 523-527
23. Ghadessy F.J., Lim J., Abdullah A.A., Panet-Raymond V., Choo C.K., Lumbroso R., Tut T.G., Gottlieb B., Pinsky L., Trifiro M.A., and Yong E.L. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions. J. Clin. Invest. 103 (1999) 1517-1525
24. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz Jr. K.M., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., and Kollman P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117 (1995) 5179-5197
25. Li Z., and Scheraga H.A. Monte Carlo minimization approach to the multiple-minima problem in protein folding. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 6611-6615
26. Naim M., Bhat S., Rankin K.N., Dennis S., Chowdhury S.F., Siddiqi I., Drabik P., Sulea T., Bayly C., Jakalian A., and Purisima E.O. Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. J. Chem. Inf. Model. 47 (2007) 122-133
27. Purisima E.O. Fast summation boundary element method for calculating solvation free energies of macromolecules. J. Comput. Chem. 19 (1998) 1494-1505
28. Ding D., Xu L., Menon M., Reddy G.P., and Barrack E.R. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 58 (2004) 23-32
29. Taplin M.E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B., and Balk S.P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59 (1999) 2511-2515
30. Chen G., Shukeir N., Potti A., Sircar K., Aprikian A., Goltzman D., and Rabbani S.A. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 (2004) 1345-1356
31. Song L.N., and Gelmann E.P. Interaction of β-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J. Biol. Chem. 280 (2005) 37853-37867
32. 2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275 (2000) 22986-22994
33. Wang Q., Udayamakur T.S., Vasiatis T.S., Brodie A.M., and Fondell J.D. Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells. J. Biol. Chem. 279 (2004) 17319-17328
34. Ghali S.A., Gottlieb B., Lumbroso R., Beitel L.K., Elhaji Y., Wu J., Pinsky L., and Trifiro M.A. The use of androgen receptor amino/carboxyl terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity. J. Clin. Endocrinol. Metab. 88 (2003) 2185-2193
35. Song L.N., Coghlan C., and Gelmann E.P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 18 (2004) 70-75
36. He B., Gampe Jr. R.T., Hnat A.T., Faggart J.L., Minges J.T., French F.S., and Wilson E.M. Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. J. Biol. Chem. 281 (2006) 6648-66463
37. Duff J., and McEwan I.J. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol. Endocrinol. 19 (2005) 2943-2954